What Clinicians Should Know About Surrogate Endpoints in Hematologic Malignancies.
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood.2023022269
Abstract: Use of surrogates as primary endpoints is commonplace in hematology/oncology clinical trials. As opposed to prognostic markers, surrogates are endpoints that can be measured early and yet can still capture the full effect of treatment,… read more here.
Keywords: know surrogate; hematologic malignancies; hematology; clinicians know ... See more keywords